How Cannabis Can Help America Out Of The Opioid Crisis

PLAY VIDEO
SHARE VIDEO

The Cannabis Solution

The Exit Drug documentary, created by Weedmaps, investigates how cannabis could play a major role in ending the opioid crisis, a public health emergency that kills an average of 115 U.S. citizens a day¹⁹. According to neuroscientist Dr. Adie Wilson-Poe, cannabis has the potential to significantly improve public health by diminishing our reliance on opioids. The Exit Drug explores the course of opioid addiction, from initial usage (typically after an injury) to drug relapse, and how cannabis could be the solution to reduce harm and promote help.

STARTING THE CONVERSATION

Are you or a loved one seeking help? For some, the discussion of using cannabis as a medical treatment might be as difficult as discussing opioids. We’ve provided a document with talking points and information about how cannabis can be used as a substitute and treatment for opioids. Download our document and start the conversation with your doctor.

DOWNLOAD DOCUMENT

DOWNLOAD DOCUMENT

SOURCES
  1. Bachhuber MA, Saloner B, Cunningham CO, Barry CL. Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. JAMA Intern Med. 2014;174(10):1668-73. doi: 10.1001/jamainternmed.2014.4005. PubMed PMID: 25154332; PMCID: 4392651.
  2. Kim JH, Santaella-Tenorio J, Mauro C, Wrobel J, Cerda M, Keyes KM, Hasin D, Martins SS, Li G. State Medical Marijuana Laws and the Prevalence of Opioids Detected Among Fatally Injured Drivers. Am J Public Health. 2016;106(11):2032-7. doi: 10.2105/AJPH.2016.303426. PubMed PMID: 27631755; PMCID: PMC5055785.
  3. Shi Y. Medical marijuana policies and hospitalizations related to marijuana and opioid pain reliever. Drug Alcohol Depend. 2017;173:144-50. doi: 10.1016/j.drugalcdep.2017.01.006. PubMed PMID: 28259087; PMCID: PMC5385927.
  4. Boehnke KF, Litinas E, Clauw DJ. Medical Cannabis Use Is Associated With Decreased Opiate Medication Use in a Retrospective Cross-Sectional Survey of Patients With Chronic Pain. J Pain. 2016;17(6):739-44. doi: 10.1016/j.jpain.2016.03.002. PubMed PMID: 27001005.
  5. Haroutounian S, Ratz Y, Ginosar Y, Furmanov K, Saifi F, Meidan R, Davidson E. The Effect of Medicinal Cannabis on Pain and Quality-of-Life Outcomes in Chronic Pain: A Prospective Open-label Study. Clin J Pain. 2016;32(12):1036-43. doi: 10.1097/AJP.0000000000000364. PubMed PMID: 26889611.
  6. Gruber SA, Sagar KA, Dahlgren MK, Racine MT, Smith RT, Lukas SE. Splendor in the Grass? A Pilot Study Assessing the Impact of Medical Marijuana on Executive Function. Front Pharmacol. 2016;7:355. doi: 10.3389/fphar.2016.00355. PubMed PMID: 27790138; PMCID: PMC5062916.
  7. Bradford AC, Bradford WD. Medical Marijuana Laws Reduce Prescription Medication Use In Medicare Part D. Health Aff (Millwood). 2016;35(7):1230-6. doi: 10.1377/hlthaff.2015.1661. PubMed PMID: 27385238.
  8. Bradford AC, Bradford WD. Medical Marijuana Laws May Be Associated With A Decline In The Number Of Prescriptions For Medicaid Enrollees. Health Aff (Millwood). 2017;36(5):945-51. doi: 10.1377/hlthaff.2016.1135. PubMed PMID: 28424215.
  9. Roberts JD, Gennings C, Shih M. Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. European journal of pharmacology. 2006;530(1-2):54-8. Epub 2005/12/27. doi: 10.1016/j.ejphar.2005.11.036. PubMed PMID: 16375890.
  10. Abrams DI, Couey P, Shade SB, Kelly ME, Benowitz NL. Cannabinoid-opioid interaction in chronic pain. Clinical pharmacology and therapeutics. 2011;90(6):844-51. Epub 2011/11/04. doi: 10.1038/clpt.2011.188. PubMed PMID: 22048225.
  11. Wilson AR, Maher L, Morgan MM. Repeated cannabinoid injections into the rat periaqueductal gray enhance subsequent morphine antinociception. Neuropharmacology. 2008;55(7):1219-25. doi: 10.1016/j.neuropharm.2008.07.038. PubMed PMID: 18723035; PMCID: 2743428.
  12. Smith PA, Selley DE, Sim-Selley LJ, Welch SP. Low dose combination of morphine and delta9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors. European journal of pharmacology. 2007;571(2-3):129-37. Epub 2007/07/03. doi: 10.1016/j.ejphar.2007.06.001. PubMed PMID: 17603035; PMCID: 2040345.
  13. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain – United States, 2016. MMWR Recomm Rep. 2016;65(1):1-49. doi: 10.15585/mmwr.rr6501e1. PubMed PMID: 26987082.
  14. NASEM. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington (DC)2017.
  15. Reiman A, Welty M, Solomon P. Cannabis as a Substitute for Opioid-Based Pain Medication: Patient Self-Report. Cannabis Cannabinoid Res. 2017;2(1):160-6. doi: 10.1089/can.2017.0012. PubMed PMID: 28861516; PMCID: PMC5569620.
  16. Hurd YL, Yoon M, Manini AF, Hernandez S, Olmedo R, Ostman M, Jutras-Aswad D. Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage. Neurotherapeutics. 2015;12(4):807-15. doi: 10.1007/s13311-015-0373-7. PubMed PMID: 26269227; PMCID: PMC4604178.
  17. Raby WN, Carpenter KM, Rothenberg J, Brooks AC, Jiang H, Sullivan M, Bisaga A, Comer S, Nunes EV. Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence. Am J Addict. 2009;18(4):301-8. doi: 10.1080/10550490902927785. PubMed PMID: 19444734; PMCID: PMC2753886.
  18. Rossi, S., G. Bernardi, and D. Centonze. The endocannabinoid system in the inflammatory and neurodegenerative processes of multiple sclerosis and of amyotrophic lateral sclerosis. Experimental Neurology. 2010. Exp Neurol. 2010 Jul;224(1):92-102. doi: 10.1016/j.expneurol.2010.03.030. Epub 2010 Mar 29.
  19. Rudd RA, Seth P, David F, Scholl L. Increases in Drug and Opioid-Involved Overdose Deaths — United States, 2010–2015. MMWR Morb Mortal Wkly Rep 2016;65:1445–1452. DOI: http://dx.doi.org/10.15585/mmwr.mm655051e1